Prosperous Health: Revolutionizing Behavioral Healthcare Through Expertise and Innovation
Prosperous Health's leadership team brings a unique blend of clinical knowledge and personal recovery experience. CEO JD Meints, who has 13 years of sobriety and over a decade of facility operations experience, says that the company's approach 'allows facilities to focus on their core mission: delivering exceptional care to patients.' Having created multiple nationally recognized programs, including one of the first virtual PHP/IOP offerings in the country, he emphasizes the importance of meeting modern treatment demands.
COO Jerry Shirey, himself with 11 years in recovery, adds that their model 'goes beyond traditional treatment' by integrating technology, evidence-based practices, and compassionate support systems. Shirey's background includes securing more than $25 million in grant funding and leading the introduction of the first ASAM 3.3 Level of Care in the region. His expertise in bridging clinical strategies with innovative solutions has helped shape the way Prosperous Health expands treatment options.
The company's leadership is further strengthened by Chief Medical Officer Dr. Matin Hemmat, a board-certified specialist in both Addiction Medicine and Internal Medicine and a recipient of multiple 'Physician of the Year' awards. His focus ensures that Prosperous Health maintains cutting-edge medical practices centered on patient welfare and measurable outcomes.
As an MSO, Prosperous Health provides comprehensive administrative and operational support, relieving facilities of regulatory and compliance burdens and enabling them to dedicate more resources to direct patient care. This specialization in behind-the-scenes logistics helps align clinical excellence with efficient and sustainable operations, addressing pressing industry challenges.
One of the company's most notable innovations is its Recovery Campus Concept, which reimagines the physical design of treatment settings. Rather than adhering to institutional layouts, these campuses bring together various levels of care—PHP, IOP, and OP—into an integrated environment specifically designed to foster healing and recovery. This thoughtful approach offers continuity for patients, ensuring they receive a seamless experience from intake to continuing care.
Prosperous Health also recognizes that many individuals lack access to in-person treatment. To tackle this challenge, it has embraced technology-based solutions, developing HIPAA-secure digital platforms that enable facilities to reach underserved communities or those who simply cannot attend treatment on-site. By integrating telehealth services, Prosperous Health meets modern healthcare realities and ensures more people can find the specialized support they need.
In addition to offering comprehensive administrative services and forward-thinking treatment models, Prosperous Health sets higher standards for the industry at large. Through new facility designs and pioneering programs, it aims to establish benchmarks that can be adapted by other providers. The introduction of the first ASAM 3.3 Level of Care in the region exemplifies this leadership, as it provides a template for broader implementation of advanced treatment modalities.
'Together, we are not just managing facilities—we are redefining how care is delivered and transforming the lives of thousands,' Shirey observes, reflecting the collective vision that drives Prosperous Health forward. As the organization prepares to open its newest facility, it stands at the intersection of operational innovation, clinical expertise, and a profound commitment to making treatment both accessible and effective.
With behavioral health challenges expanding, Prosperous Health's blueprint demonstrates how evolving beyond conventional frameworks can offer life-changing support to those who need it most. By blending operational efficiency, evidence-based practices, and cutting-edge technology, the company shows what is possible for the future of mental health and substance use disorder treatment.
Release ID: 89157174
If you encounter any issues, discrepancies, or concerns regarding the content provided in this press release that require attention or if there is a need for a press release takedown, we kindly request that you notify us without delay at error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team will be available round-the-clock to address your concerns within 8 hours and take necessary actions to rectify any identified issues or guide you through the removal process. Ensuring accurate and reliable information is fundamental to our mission.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Magazine
25-07-2025
- Time Magazine
The ‘Big Beautiful Bill' May Lead to More Fatal Overdoses
The sweeping tax and spending package that President Donald Trump signed into law earlier this month could cause thousands of people to lose access to treatment for opioid use disorder, leading to roughly 1,000 additional overdose deaths each year, researchers estimate. Fatal overdoses have been on the decline since they reached a record high in 2022. Drug policy and health experts have widely credited the drop to public health measures, such as investing in treatments, expanding therapies, and decreasing stigma. But now, they fear that Trump's 'Big Beautiful Bill' will undo that progress. The day before the bill passed the House, a group of researchers sent a memo to House Speaker Mike Johnson and Senate Majority Leader John Thune, estimating that the package would cause about 156,000 people to lose access to treatment for opioid use disorder. The next day, the bill cleared the House, and the day after, Trump signed it into law. 'I'm angry,' says Dr. Benjamin Linas, the lead researcher behind the memo and a professor of medicine and epidemiology at Boston University. 'I think it's a terrible policy. I think it's doing nothing but making America unhealthy and increasing misery.' The bill's provisions targeting Medicaid are expected to leave about 7.8 million people without health insurance in 2034 due to loss of coverage under the program, according to the Congressional Budget Office. Using that estimate, Linas and his colleagues projected, based on previous data about the proportion of people on Medicaid who receive medications for opioid use disorder, how many of those people will likely lose access to treatments. They then used simulation modeling to estimate how many additional fatal overdoses would occur in one year. Linas called the findings 'upsetting,' adding that the 1,000 additional deaths researchers projected was likely an underestimate because he and his colleagues only accounted for people not being able to access their medications for opioid use disorder—not for any other health complications that could worsen after losing access to health insurance, such as infections, heart attack, or cancer. Researchers also didn't account for the possibility that Medicaid cuts could cause some people to lose access to their preferred medication, forcing them to use a different option, which could cause 'misery and suffering and death,' Linas says. 'It's well-known and documented that when people can't get the treatment that's effective for them or that they would choose, the treatments are less effective and they fall out of care,' Linas says. American Society of Addiction Medicine (ASAM) President Dr. Stephen Taylor, who was not involved in writing the memo, says that while the impacts of the bill will vary from state to state, he found the researchers' findings to be reasonable. He notes that the bill has some provisions for people with substance use disorder, including exempting them from work requirements. 'Our focus at ASAM is just to try to mitigate some of the harms from the bill [and] make sure that these exemptions … will be implemented in as expansive and as generous a way as possible,' Taylor says. 'We want to prevent people from losing the coverage that they need; otherwise, those exemptions will be meaningless.' But Linas also points out that many people who are struggling with addiction are not diagnosed, which could make it difficult for them to access such exemptions. Overdose deaths declined by nearly 27% in the U.S. from 2023 to 2024, according to data released by the U.S. Centers for Disease Control and Prevention (CDC) in May. That comes out to about 81 lives saved each day, the CDC estimated. The number of overdose deaths specifically involving opioids plummeted from roughly 83,140 in 2023 to 54,743 in 2024, according to the CDC. In a statement, the CDC said the federal government has increased efforts to tackle the issue since Trump declared the opioid epidemic a public health emergency in October 2017, months into his first term. Since Trump returned to office in January, however, his second Administration has proposed sweeping cuts to programs dedicated to addiction treatment and research, while its efforts to address the crisis have focused on combatting drug trafficking from other countries. Many public health and addiction experts have criticized the aggressive strategy, saying that it doesn't effectively address the drug crisis. Linas says to attribute the decline in overdose deaths to cracking down on drug dealers and the border is 'completely false;' instead, he says, the credit should go to bolstering public health measures. The damage the tax and spending package is projected to wreak in opioid treatment, he says, exemplifies broader problems in how the Trump Administration is governing. 'After working so hard and seeing progress, to take such a step back is really depressing,' Linas says. 'It's also a microcosm of the total chaos that this Administration imposes on all of us. Because as recently as a year ago, we were investing a lot of federal dollars to reverse the course of this overdose epidemic and starting to see results, and now we're just going to pick up a 180 and reverse it—it's pretty miserable.'
CNBC
23-07-2025
- CNBC
Europe's most valuable firm SAP flags U.S. trade slowdown but says Japan deal gives 'hope'
German software giant SAP said Wednesday that U.S. tariff tensions were slowing down its customers' decision-making, but that the Japan trade deal announced Tuesday was cause for cautious optimism. "In some sectors which are most affected by these [policy] decisions, like public sector U.S. and also the very big manufacturing industrial companies with complicated global supply chains, there was the one or other large transaction which has slipped over the turn of the last quarter," SAP Chief Financial Officer Dominik Asam told CNBC's "Europe Early Edition." Deals were not disappearing entirely, but approvals were being passed higher up the chain of command and holding up processes due to uncertainty, he noted. "Now we have to see how quickly we can catch up. That is very much a question of how the overall environment will evolve. I mean, obviously the most recent developments in Japan give us some hope, but too early to speculate on that," Asam said. "The faster the uncertainty abates, the more confidence we have in the outcome for the full year," he added. SAP in March became Europe's biggest listed company, overtaking French luxury group LVMH and Ozempic-maker Novo Nordisk in market capitalization, after pivoting the business firstly toward cloud computing and then toward opportunities in artificial intelligence. SAP now brings in the majority of its revenue from cloud services, and has focused on how AI can tap into its huge set of finance, sales and supply chain data to make efficiencies for businesses. The U.S. is one of its core markets, and investors have been questioning how SAP would be impacted by a potential pullback in spending as the administration of President Donald Trump engages in tense trade disputes and tariff negotiations with much of the world. The status of any framework deal with the European Union remained mired in uncertainty as of Wednesday, but global stock markets were buoyed by the announcement Tuesday of an agreement with Japan setting tariffs on its exports to the U.S. at 15%. SAP reported late on Tuesday a 9% year-on-year revenue rise to 9.03 billion euros ($10.6 billion) in the second quarter, just shy of an LSEG-compiled consensus forecast of 9.08 billion euros. Operating profit was just ahead of estimates at 2.57 billion euros. The company reiterated its full-year 2025 outlook, despite noting that the "prevailing dynamic environment implies elevated levels of uncertainty and reduced visibility." On an analyst call Tuesday, CEO Christian Klein said SAP was seeing "strong momentum" from the recent national security spending push in Europe, which has driven massive gains in defense stocks this year, some of which are SAP customers. Its current cloud backlog, a key metric for the firm, was up 28% on a constant currency basis to 18.05 billion, which analysts at Deutsche Bank said were "strong" in a Wednesday note. "Overall, we see SAP continuing to execute very well in a challenging environment, helped by its strong product offerings, AI roadmap and structural long-term Cloud migration projects. New wins included landmark customers such as Alibaba in Q2," the Deutsche Bank analysts said. However, other reactions were less positive, with analysts at TD Cowen and Piper Sandler trimming their target prices on the stock. One drag on the results came from fluctuations in foreign exchange rates, particularly weakness in the U.S. dollar against the euro, in which SAP reports. The firm forecast a 5 percentage-point drag on cloud revenue growth figures in the third quarter, assuming exchange rates as of June 30. SAP's Frankfurt-listed shares were 3.5% lower in early deals on Wednesday.
Medscape
17-07-2025
- Medscape
Rapid Rx Quiz: Opioid Overdose
Recent efforts in prevention, treatment, and harm reduction have led to encouraging signs of progress in the opioid epidemic. Increased public awareness, expanded access to naloxone, and evolving prescribing practices have all contributed to a decline in overdose deaths. However, due to the widespread availability of synthetic opioids (particularly fentanyl), clinicians must remain vigilant because overdose presentations are becoming increasingly complex and resistant to standard interventions. Effective management requires rapid clinical decision-making and a thorough understanding of opioid pharmacology and toxicity. How much do you know about managing opioid overdose? Test yourself with this quick quiz. Activation of cardiac opioid receptors during overdose leads to membrane hyperpolarization and increased vagal tone. These effects promote bradycardia and peripheral vasodilation, both of which can lead to hypotension. In addition, systemic histamine release can further intensify vasodilation and might result in profound hypotension. Learn more about the pathophysiology of opioid toxicity. According to ASAM guidelines, naloxone should be administered to all pregnant women experiencing an opioid overdose to prioritize maternal survival. Delaying or withholding naloxone during overdose due to concerns about fetal effects is not recommended. Although naloxone might precipitate opioid withdrawal, this risk is outweighed by the need to reverse potentially fatal respiratory depression. Learn more about the presentation of opioid toxicity. Buprenorphine has an exceptionally high affinity for the mu opioid receptor, making it difficult to displace with naloxone. A bolus dose of naloxone is recommended to achieve a high enough serum concentration to begin competitively binding at these receptor sites. Continuous infusion alone might be insufficient to rapidly reverse respiratory depression without an initial bolus. Hemodialysis is not an effective treatment for buprenorphine overdose, and avoiding dialysis is not a relevant consideration. Although benzodiazepines are commonly co-ingested with buprenorphine and might contribute to respiratory depression, this does not explain the need for a naloxone bolus, because naloxone does not reverse benzodiazepine effects. Buprenorphine has a long half-life compared to many other opioid drugs, but this affects the duration of monitoring and the potential need for prolonged naloxone infusion, not the decision to administer a bolus dose. Learn more about buprenorphine/naloxone toxicity. Recommended criteria for emergency department discharge following 6-12 hours of observation after naloxone reversal of opioid overdose include an oxygen saturation ≥ 92% on room air. Other criteria include a Glasgow Coma Scale score of 15, a respiratory rate ≥ 10 breaths/min, and blood pressure between 110/90 mm Hg and 140/90 mm Hg. These parameters help confirm sustained clinical stability following naloxone reversal. Learn more about emergency department care of opioid toxicity. Fentanyl exhibits a biphasic plasma concentration profile, with an initial peak followed by a decline. However, in overdose, secondary plasma peaks might occur 45-60 minutes or even hours later, a phenomenon referred to as 'fentanyl rebound.' These delayed increases in fentanyl concentration have been linked to new or recurrent respiratory depression, sometimes requiring additional naloxone. Nalmefene injection or nalmefene intranasal are other options for treating fentanyl overdose. Nalmefene has a longer half-life than naloxone. Despite rapid hepatic metabolism, fentanyl has a prolonged and variable duration of effect due to redistribution into peripheral tissues. Because fentanyl is highly lipophilic, it readily accumulates in tissues like muscle and fat, especially with repeated use. Fentanyl-induced skeletal muscle rigidity, including the chest wall rigidity known as wooden chest syndrome, typically occurs within minutes of exposure. This complication can make airway management more difficult in overdose scenarios. Learn more about fentanyl.
